More than 17 million treatments are performed globally each year for diabetic foot ulcers (DFU) with half of those becoming infected¹

Repeated courses of antibiotics to treat DFUs risk greater incidences of antimicrobial resistance

US hospitalization costs for infected DFUs: 11,000 to 15,000 USD per patient

The most frequent bacteria associated with DFU include Staphylococcus aureus, Pseudomonas aeruginosa, E. Coli and five other catalase positive microbes

Demonstrated photoinactivation of catalase to enhance bacteria reduction with ROS or ROS generating agents could be instrumental in preventing and treating infected DFUs

Acne vulgaris affects 80% of young adults; can induce permanent disfigurement 

The mainstay of therapeutics consist of eradicating C. acnes and reducing inflammation; however, treatment has been associated with the emergence of antibiotic resistance

Resistance to two first line antibiotics, clindamycin and erythromycin, currently stands at 30-50%

Blue light LED devices (outside the 410-430nm range) and benzoyl peroxide are often used separately to treat acne with some effectiveness

Pulsethera’s technology, in combination with benzoyl peroxide, has been demonstrated to kill C. acnes in vitro

Candida colonization and infection of skin can result in deeper invasive infections with unacceptably high mortality of 50-90% and account for 10% of all intensive care unit admissions.

C. auris, with multi-drug resistance and the ability to colonize skin and surfaces for prolonged periods of time, is responsible for the closure of health care facilities globally

Pulsethera’s technology, in combination with hydrogen peroxide, has been demonstrated to kill Candida in vitro